COVID-19-Associated Liver Injury

Daniel T Gildea,1 Stephanie M Woo,2 Corinne E O’Connor,3 Amol S Rangnekar4 1Department of Internal Medicine, MedStar Georgetown University Hospital, Washington, DC, USA; 2Department of Gastroenterology, MedStar Georgetown University Hospital, Washington, DC, USA; 3Georgetown University School of Medicine, Washington, DC, USA; 4MedStar Georgetown Transplant Institute, MedStar Georgetown University Hospital, Washington, DC, USACorrespondence: Daniel T Gildea, Tel +1 302-985-7777, Email daniel.gildea@medstar.netAbstract: This review analyzes data regarding liver injury associated with COVID-19 infection. We discuss reported effects on the liver from both COVID-19 and COVID-19 treatment as well as pathophysiology, review the potential role of drug-induced liver injury as an etiology of COVID-19-associated liver injury, and touch on other reports of significant outcomes including COVID-19 cholangiopathy and autoimmune hepatitis. Finally, we review the implications of COVID-19 infection in liver transplant recipients.Keywords: COVID-19, cholangiopathy, DILI, hepatitis, transplant, liver